Immunovaccine (TSX-V:IMV), is a clinical stage vaccine development company focused on the commercialization of its patented DepoVax™ vaccine delivery technology. The company continues to strengthen its vaccine pipeline, through licensing and strategic partnerships.
In R&D, Immunovaccine continues to strengthen its vaccine pipeline to develop therapeutic cancer and infectious disease vaccines. The company’s lead product DPX-0907, a DepoVax-based therapeutic cancer vaccine, is in a Phase 1 clinical trial in the US.